SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6311)5/10/2002 2:35:48 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
george,

I think that the AC will vote to approve Amevive, but that there will be some dissension. Further, given the intense competition in this area, I expect any Amevive problems will be thoroughly reported. In the current FDA environment, anything else but a sparkling vote of approval risks delays from the FDA.

A biologic for psoriasis is new territory, and so the AC and FDA will take a cautious approach.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News